Tom 4, Nr 3 (2019)
Artykuł przeglądowy
Opublikowany online: 2019-09-30
Wyświetlenia strony
1229
Wyświetlenia/pobrania artykułu
1079
Skuteczność i bezpieczeństwo ultra- oraz niskodawkowej dwuskładnikowej antykoncepcji hormonalnej a wiek i masa ciała kobiet
1
Ginekologia i Perinatologia Praktyczna 2019;4(3):123-128.
Streszczenie
Ultraniskodawkowa (15 μg etynyloestradiolu) dwuskładnikowa tabletka antykoncepcyjna jest nowoczesną metodą antykoncepcyjną stosowaną u kobiet w całym okresie reprodukcyjnym (18–50 lat) i o zróżnicowanym profilu masy ciała (również u kobiet otyłych). W pracy przeanalizowano potencjalny wpływ wieku, masy ciała oraz indeksu masy ciała na skuteczność DTA z uwzględnieniem prac farmakokinetycznych i obserwacyjnych badań klinicznych. Analizie poddano również badania i rekomendacje dotyczące bezpieczeństwa DTA oraz potencjalnego ryzyka rozwoju żylnej choroby zatorowo-zakrzepowej u palaczek papierosów. Ponadto omówiono mechanizmy, które prowadzą do zmniejszenia spektrum objawów ubocznych u kobiet stosujących DTA, z uwzględnianiem schematu dawkowania 24/4 i ultraniskich dawek estrogenów.
Słowa kluczowe: antykoncepcjaultraniskodawkowaskutecznośćwiekotyłość
Referencje
- Statystyczny GU. Stan Zdrowia Ludności w Polsce w 2009 roku. Warszawa: Główny Urząd Statystyczny; 2011.
- Population. 2017.
- Leo VDe, Musacchio M, Cappelli V, et al. Hormonal contraceptives: pharmacology tailored to women's health. Human Reproduction Update. 2016; 22(5): 634–646.
- 322 GSG. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. 1999;4 :9-15. Epub 2003/12/18. PubMed PMID. ; 14677620(Suppl 2).
- 324 GSG. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. 1999;4 :17-25. Epub 2003/12/18. PubMed PMID. ; 14677621(Suppl 2).
- Stanczyk F, Archer D. Gestodene: A review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014; 89(4): 242–252.
- Sullivan H, Furniss H, Spona J, et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril. 1999; 72(1): 115–120.
- Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care. 2010; 15(1): 4–16.
- Poindexter A. The emerging use of the 20-μg oral contraceptive. Fertility and Sterility. 2001; 75(3): 457–465.
- Gallo M, Nanda K, Grimes D, et al. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews. 2013.
- Safety and eligibility for hormonal and intrauterine contraceptions--Polish Gynecological Society Recommendation . Ginekologia polska. 2014; 85(3): 234–239.
- WHO WHO. Guidelines Approved by the Guidelines Review Committee. Medical Eligibility Criteria for Contraceptive Use: A WHO Family Planning Cornerstone. 5th ed. Geneva: World Health Organization. ; 2015.
- Nappi C, Sardo AD, Acunzo G, et al. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception. 2003; 67(5): 355–359.
- Simmons K, Edelman A. Hormonal contraception and obesity. Fertility and Sterility. 2016; 106(6): 1282–1288.
- Westhoff C, Torgal A, Mayeda E, et al. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception. 2010; 81(6): 474–480.
- Edelman A, Carlson N, Cherala G, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic–pituitary–ovarian activity. Contraception. 2009; 80(2): 119–127.
- Edelman A, Cherala G, Munar M, et al. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. Contraception. 2013; 87(2): 220–226.
- Jusko W. Clarification of contraceptive drug pharmacokinetics in obesity. Contraception. 2017; 95(1): 10–16.
- Edelman A, Cherala G, Munar M, et al. Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. Contraception. 2014; 90(5): 550–556.
- Luo D, Westhoff C, Edelman A, et al. Altered pharmacokinetics of combined oral contraceptives in obesity — multistudy assessment. Contraception. 2019; 99(4): 256–263.
- Lopez LM, Bernholc A, Chen M, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2016(8): CD008452.
- Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. The European Journal of Contraception & Reproductive Health Care. 2011; 16(6): 430–443.
- Westhoff C, Hait H, Reape K. Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive. Contraception. 2012; 85(3): 235–239.
- Nakajima S, Pappadakis J, Archer D. Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive. Contraception. 2016; 93(1): 52–57.
- Burkman R, Fisher A, Wan G, et al. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception. 2009; 79(6): 424–427.
- Kaunitz A, Portman D, Westhoff C, et al. Low-Dose Levonorgestrel and Ethinyl Estradiol Patch and Pill. Obstetrics & Gynecology. 2014; 123(2, PART 1): 295–303.
- Dragoman M, Simmons K, Paulen M, et al. Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review. Contraception. 2017; 95(2): 117–129.
- Vessey M. Oral contraceptive failures and body weight: findings in a large cohort study. J Fam Plann Reprod Health Care. 2001; 27(2): 90–91.
- Dinger JC, Bardenheuer K, Assmann A. International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study). BMC Med Res Methodol. 2009; 9: 77.
- Dinger J, Heinemann L, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception. 2007; 75(5): 344–354.
- Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002; 77(2 Suppl 2): S13–S18.
- Yamazaki M, Dwyer K, Sobhan M, et al. Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysis. Contraception. 2015; 92(5): 445–452.
- Hugon-Rodin J, Gompel A, Plu-Bureau G. MECHANISMS IN ENDOCRINOLOGY: Epidemiology of hormonal contraceptives-related venous thromboembolism. European Journal of Endocrinology. 2014; 171(6): R221–R230.
- de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014(3): CD010813.
- Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016: i2002.
- Stegeman BH, Bastos Mde, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013; 347(sep12 1): f5298–f5298.
- Barbosa I, Filho C, Faggion D, et al. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 μg and ethinylestradiol 15 μg (Minesse®). Contraception. 2006; 73(1): 30–33.
